4th Quarter - Report

ROCK & ASSOCIATES for US COMPOUNDING

Period 4th Quarter 2013 Filed Jan 13, 2014 Signed by James W. Rock, President

Official filing
Firm
ROCK & ASSOCIATES
Client
US COMPOUNDING
Income
$11,250
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.959, H.R. 3089 & H.R. 3204 legislation affecting the operation of compounding pharmacies and the availability of compounded medications.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3089 (113th), H.R. 3204 (113th), S. 959 (113th)

Pharmacy PHA

S.959, H.R. 3089 & H.R. 3204 legislation affecting the operation of compounding pharmacies and the availability of compounded medications.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 959 (113th), H.R. 3204 (113th), H.R. 3089 (113th)

Medical/Disease Research/Clinical Labs MED

S.959, H.R. 3089 & H.R. 3204 legislation affecting the operation of compounding pharmacies and the availability of compounded medications.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 959 (113th), H.R. 3089 (113th), H.R. 3204 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.